Entity

Time filter

Source Type

Versailles, France

Versailles Saint-Quentin-en-Yvelines University is a French public university created in 1991, located in the department of Yvelines and since 2002 in Hauts-de-Seine. It is mainly located in the cities of Versailles, Saint-Quentin-en-Yvelines, Mantes-en-Yvelines and Vélizy-Villacoublay / Rambouillet, with a total of eight campuses. It is one of the five universities of the Academy of Versailles.It is one of the four universités nouvelles inaugurated in Île-de-France region after the plan université 2000 . It has 19,000 students, 752 staff people and 1,389 teachers and researchers. 285 teachers outside of the university come each year to provide courses.The subjects taught are the exact science, the social science, the political science, engineering, technology and medicine. It also provide courses concerning the relationship between economy, ethics, natural environment and sustainable development. Wikipedia.


Serre C.,University of Versailles
Angewandte Chemie - International Edition | Year: 2012

A new job: Highly fluorinated porous MOFs (see picture) that exhibit a superior hydrophobic character can possibly find an application as new superhydrophobic adsorbents in aqueous-phase separation processes. Copyright © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. Source


Patent
Institute Gustave Roussy, French Institute of Health, Medical Research, Assistance Publique Hopitaux De Paris, University of Versailles and University Paris - Sud | Date: 2014-01-27

The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.


Patent
French Atomic Energy Commission, French National Center for Scientific Research, University of Versailles and University Paris - Sud | Date: 2015-10-08

A process for preparing a porous solid with an outer surface modified by at least one polymer; the polymer being simultaneously synthetized in solution and grafted on the outer surface of the solid, includes contacting:


The present invention relates to a pharmaceutical composition for treating the human immunodeficiency virus (HIV) in a human being, comprising four active principles selected as being: one nucleoside inhibitor of reverse transcriptase (NRTI) selected from lamivudine and emtricitabine; two nucleoside or nucleotide inhibitor of reverse transcriptase (NRTI) selected from didanosine, abacavir and tenofovir; and the fourth active principle is selected from (i) a non-nucleoside inhibitor of reverse transcriptase (NNRTI) selected from nevirapine, efavirenz and etravirine; or (ii) a protease inhibitor selected from atazanavir, lopinavir, saquinavir, ritonavir, indinavir, amprenavir, nelfinavir, fosamprenavir, tipranavir and darunavir. The present invention also relates to an electronic portable pillbox comprising a multidrug therapy for treating the immunodeficiency virus (HIV) in human beings allowing improving the observance of medication intake.


Patent
Mitologics, French National Center for Scientific Research and University of Versailles | Date: 2014-06-05

ANT-ligands having a substituted nitrogeneous heterocycle A wherein wherein wherein wherein,

Discover hidden collaborations